|
LM_ID
|
Common Name
|
Systematic Name
|
Main class
|
Sub class
|
Mass
|
Formula
|
|
LMFA04000078
|
4,5-epoxy-17R-HDHA
|
4,5-epoxy-17R-hydroxy-6E,8E,10Z,13Z,15E,19Z-docosahexaenoic acid
|
Docosanoids [FA04]
|
Other Docosanoids [FA0400]
|
358.21
|
C22H30O4
|
|
LMFA04000013
|
7,8-epoxy-17S-HDHA
|
7,8-epoxy-17S-hydroxy-4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid
|
Docosanoids [FA04]
|
Other Docosanoids [FA0400]
|
358.21
|
C22H30O4
|
|
LMFA04000073
|
7S,8S-epoxy-17R-HDHA
|
7S,8S-epoxy-17R-hydroxy-4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid
|
Docosanoids [FA04]
|
Other Docosanoids [FA0400]
|
358.21
|
C22H30O4
|
|
LMFA04000070
|
7S,8S-epoxy-17S-HDHA
|
7S,8S-epoxy-17S-hydroxy-4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid
|
Docosanoids [FA04]
|
Other Docosanoids [FA0400]
|
358.21
|
C22H30O4
|
|
LMFA04010413
|
10,13-diepi-10-A4-NeuroP
|
(R,4Z,7Z,11E)-10-hydroxy-12-((1S,5R)-2-oxo-5-((Z)-pent-2-en-1-yl)cyclopent-3-en-1-yl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010477
|
10,13-diepi-10-J4-NeuroP
|
(R,4Z,7Z,11E)-10-hydroxy-12-((1R,5S)-4-oxo-5-((Z)-pent-2-en-1-yl)cyclopent-2-en-1-yl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010445
|
10,17-diepi-17-A4-NeuroP
|
(4Z,7Z)-9-((1S,2R)-2-((R,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-5-oxocyclopent-3-en-1-yl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010509
|
10,17-diepi-17-J4-NeuroP
|
(4Z,7Z)-9-((1R,5S)-5-((R,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-4-oxocyclopent-2-en-1-yl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010415
|
10-A4-NeuroP
|
(S,4Z,7Z,11E)-10-hydroxy-12-((1R,5R)-2-oxo-5-((Z)-pent-2-en-1-yl)cyclopent-3-en-1-yl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010479
|
10-J4-NeuroP
|
(S,4Z,7Z,11E)-10-hydroxy-12-((1S,5S)-4-oxo-5-((Z)-pent-2-en-1-yl)cyclopent-2-en-1-yl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010411
|
10-epi-10-A4-NeuroP
|
(R,4Z,7Z,11E)-10-hydroxy-12-((1R,5R)-2-oxo-5-((Z)-pent-2-en-1-yl)cyclopent-3-en-1-yl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010475
|
10-epi-10-J4-NeuroP
|
(R,4Z,7Z,11E)-10-hydroxy-12-((1S,5S)-4-oxo-5-((Z)-pent-2-en-1-yl)cyclopent-2-en-1-yl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010449
|
10-epi-17-A4-NeuroP
|
(4Z,7Z)-9-((1S,2R)-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-5-oxocyclopent-3-en-1-yl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010513
|
10-epi-17-J4-NeuroP
|
(4Z,7Z)-9-((1R,5S)-5-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-4-oxocyclopent-2-en-1-yl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010409
|
10-epi-7-A4-NeuroP
|
(S,4Z,8E)-7-hydroxy-9-((1S,2R)-2-((2Z,5Z)-octa-2,5-dien-1-yl)-5-oxocyclopent-3-en-1-yl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010473
|
10-epi-7-J4-NeuroP
|
(S,4Z,8E)-7-hydroxy-9-((1R,5S)-5-((2Z,5Z)-octa-2,5-dien-1-yl)-4-oxocyclopent-2-en-1-yl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010423
|
11-A4-NeuroP
|
3-((1R,2R)-2-((S,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-5-oxocyclopent-3-en-1-yl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010487
|
11-J4-NeuroP
|
3-((1S,5S)-5-((S,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-4-oxocyclopent-2-en-1-yl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010419
|
11-epi-11-A4-NeuroP
|
3-((1R,2R)-2-((R,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-5-oxocyclopent-3-en-1-yl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010483
|
11-epi-11-J4-NeuroP
|
3-((1S,5S)-5-((R,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-4-oxocyclopent-2-en-1-yl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010429
|
13,16-diepi-13-A4-NeuroP
|
(R,4Z,7Z,10Z,14E)-15-((1S,2R)-2-ethyl-5-oxocyclopent-3-en-1-yl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010493
|
13,16-diepi-13-J4-NeuroP
|
(R,4Z,7Z,10Z,14E)-15-((1R,5S)-5-ethyl-4-oxocyclopent-2-en-1-yl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010453
|
13,20-diepi-20-A4-NeuroP
|
(4Z,7Z,10Z)-12-((1S,2R)-2-((R,E)-3-hydroxypent-1-en-1-yl)-5-oxocyclopent-3-en-1-yl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010517
|
13,20-diepi-20-J4-NeuroP
|
(4Z,7Z,10Z)-12-((1R,5S)-5-((R,E)-3-hydroxypent-1-en-1-yl)-4-oxocyclopent-2-en-1-yl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010431
|
13-A4-NeuroP
|
(S,4Z,7Z,10Z,14E)-15-((1R,2R)-2-ethyl-5-oxocyclopent-3-en-1-yl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010495
|
13-J4-NeuroP
|
(S,4Z,7Z,10Z,14E)-15-((1S,5S)-5-ethyl-4-oxocyclopent-2-en-1-yl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010417
|
13-epi-10-A4-NeuroP
|
(S,4Z,7Z,11E)-10-hydroxy-12-((1S,5R)-2-oxo-5-((Z)-pent-2-en-1-yl)cyclopent-3-en-1-yl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010481
|
13-epi-10-J4-NeuroP
|
(S,4Z,7Z,11E)-10-hydroxy-12-((1R,5S)-4-oxo-5-((Z)-pent-2-en-1-yl)cyclopent-2-en-1-yl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010427
|
13-epi-13-A4-NeuroP
|
(R,4Z,7Z,10Z,14E)-15-((1R,2R)-2-ethyl-5-oxocyclopent-3-en-1-yl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010491
|
13-epi-13-J4-NeuroP
|
(R,4Z,7Z,10Z,14E)-15-((1S,5S)-5-ethyl-4-oxocyclopent-2-en-1-yl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010457
|
13-epi-20-A4-NeuroP
|
(4Z,7Z,10Z)-12-((1S,2R)-2-((S,E)-3-hydroxypent-1-en-1-yl)-5-oxocyclopent-3-en-1-yl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010521
|
13-epi-20-J4-NeuroP
|
(4Z,7Z,10Z)-12-((1R,5S)-5-((S,E)-3-hydroxypent-1-en-1-yl)-4-oxocyclopent-2-en-1-yl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010439
|
14-A4-NeuroP
|
(Z)-6-((1R,2R)-2-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-5-oxocyclopent-3-en-1-yl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010503
|
14-J4-NeuroP
|
(Z)-6-((1S,5S)-5-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-4-oxocyclopent-2-en-1-yl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010435
|
14-epi-14-A4-NeuroP
|
(Z)-6-((1R,2R)-2-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-5-oxocyclopent-3-en-1-yl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010499
|
14-epi-14-J4-NeuroP
|
(Z)-6-((1S,5S)-5-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-4-oxocyclopent-2-en-1-yl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010433
|
16-epi-13-A4-NeuroP
|
(S,4Z,7Z,10Z,14E)-15-((1S,2R)-2-ethyl-5-oxocyclopent-3-en-1-yl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010497
|
16-epi-13-J4-NeuroP
|
(S,4Z,7Z,10Z,14E)-15-((1R,5S)-5-ethyl-4-oxocyclopent-2-en-1-yl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010447
|
17-A4-NeuroP
|
(4Z,7Z)-9-((1R,2R)-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-5-oxocyclopent-3-en-1-yl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010511
|
17-J4-NeuroP
|
(4Z,7Z)-9-((1S,5S)-5-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-4-oxocyclopent-2-en-1-yl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010443
|
17-epi-17-A4-NeuroP
|
(4Z,7Z)-9-((1R,2R)-2-((R,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-5-oxocyclopent-3-en-1-yl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010507
|
17-epi-17-J4-NeuroP
|
(4Z,7Z)-9-((1S,5S)-5-((R,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-4-oxocyclopent-2-en-1-yl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010455
|
20-A4-NeuroP
|
(4Z,7Z,10Z)-12-((1R,2R)-2-((S,E)-3-hydroxypent-1-en-1-yl)-5-oxocyclopent-3-en-1-yl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010519
|
20-J4-NeuroP
|
(4Z,7Z,10Z)-12-((1S,5S)-5-((S,E)-3-hydroxypent-1-en-1-yl)-4-oxocyclopent-2-en-1-yl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010451
|
20-epi-20-A4-NeuroP
|
(4Z,7Z,10Z)-12-((1R,2R)-2-((R,E)-3-hydroxypent-1-en-1-yl)-5-oxocyclopent-3-en-1-yl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010515
|
20-epi-20-J4-NeuroP
|
(4Z,7Z,10Z)-12-((1S,5S)-5-((R,E)-3-hydroxypent-1-en-1-yl)-4-oxocyclopent-2-en-1-yl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010421
|
4,11-diepi-11-A4-NeuroP
|
3-((1S,2R)-2-((R,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-5-oxocyclopent-3-en-1-yl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010485
|
4,11-diepi-11-J4-NeuroP
|
3-((1R,5S)-5-((R,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-4-oxocyclopent-2-en-1-yl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010397
|
4,7-diepi-4-A4-NeuroP
|
(R,E)-4-hydroxy-6-((1S,5R)-2-oxo-5-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopent-3-en-1-yl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010461
|
4,7-diepi-4-J4-NeuroP
|
(R,E)-4-hydroxy-6-((1R,5S)-4-oxo-5-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopent-2-en-1-yl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|